House passes drug price bill

Share this article:
The House of Representatives passed a bill Friday requiring government negotiation of drug prices for Medicare recipients by a vote of 255-170. The bill, promised as part of Speaker Nancy Pelosi’s “100 hours” agenda, replaced a much more ambitious plan scuttled because the Democrats wanted to avoid a rumble with pharmaceutical lobbyists, The Washington Post reported Friday. But the bill nonetheless would strike the “noninterference provision” that was part of the Medicare prescription drug benefit, which prohibits price controls, and mandates direct negotiations between Health and Human Services and drug companies over pricing. Should the bill pass through the Senate–-a prospect that seems unlikely, given Republican threats of a filibuster–-President Bush has promised to veto it. The bill’s chances in the Senate got a slight lift with the sign-on of Senate Finance Committee chairman Max Baucus, the centrist Montana Democrat, who said he believed the government should be able to negotiate prices for Medicare recipients in “discrete areas where our seniors need our help the most.”
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.